AllergoOncology, the emerging discipline of cancer immunology aiming to exploit features of allergy-related immunity to treat tumors,1-3 has catalyzed the development of tumor-specific IgE mAbs as powerful alternatives to commonly used therapeutic IgGs.4-6 IgE, which is associated typically with the pathogenesis of allergic responses and is known for Fc-mediated protective effects in parasitic infection clearance, presents exciting opportunities to unleash previously untapped immune mechanisms and effective antitumor surveillance when focused against cancer antigens.
No takes yet. Share an insight, caveat, or question.
Crescioli et al. (2018) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: